PMID: 28514566Jan 1, 2015Paper

Long-Term Pancreas Allograft Survival in Simultaneous Pancreas-Kidney Transplantation by Era

Clinical Transplants
Kayo WakiNorihiro Kokudo

Abstract

Data collected by the United Network for Organ Sharing from all approved United States transplant programs were analyzed; the data included 20,290 adult diabetic patients who received primary pancreas transplants between October 1987 and December 2014. Simultaneous pancreas-kidney (SPK) transplantation has become the major therapeutic option for diabetes patients. The number of SPKs per year has not increased since 1999; it leveled off or decreased slightly each year. Recipients in the most recent period, 2010-2014, were more likely than recipients in any of the other periods to be non-white, older, male, to have had diabetes longer, to have higher body mass indices; and in this group there were more donor-recipient human leukocyte antigen mismatches. Donors in the 2010-2014 period were more likely to be younger and male and less likely to be white. Pancreas graft survival rates were highest in the 2010-2014 period (one-year graft survival 89.7%) vs. those for 1987-1989 (74.6%), 1990- 1994 (77.5%), 1995-1999 (82.9%), 2000-2004 (84.4%), and 2005-2009 (85.5%); the five-year rates were 72.7% for 2010-14 vs. 60.0%, 64.3%, 69.0%, 70.9%, and 73.9% for the other periods, respectively. There was no decreased risk of graft failure for r...Continue Reading

Related Concepts

Related Feeds

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.